KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Sep 2025 value amounting to $184.5 million.

  • Supernus Pharmaceuticals' Accumulated Expenses rose 9.07% to $184.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.5 million, marking a year-over-year increase of 9.07%. This contributed to the annual value of $168.7 million for FY2024, which is 9.35% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Accumulated Expenses of $184.5 million as of Q3 2025, which was up 1.96% from $180.9 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Accumulated Expenses' 5-year high stood at $184.5 million during Q3 2025, with a 5-year trough of $128.7 million in Q1 2021.
  • Over the past 3 years, Supernus Pharmaceuticals' median Accumulated Expenses value was $168.7 million (recorded in 2024), while the average stood at $166.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first climbed by 20.47% in 2021, then decreased by 16.04% in 2022.
  • Supernus Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $132.7 million in 2021, then climbed by 14.27% to $151.7 million in 2022, then increased by 1.72% to $154.3 million in 2023, then grew by 9.35% to $168.7 million in 2024, then rose by 9.07% to $184.5 million in 2025.
  • Its Accumulated Expenses stands at $184.5 million for Q3 2025, versus $180.9 million for Q2 2025 and $170.1 million for Q1 2025.